Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
about
Evidence of a founder BRCA1 mutation in ScotlandIdentification of a founder BRCA2 mutation in SardiniaInvasive breast cancer following bilateral subcutaneous mastectomy in a BRCA2 mutation carrier: a case report and review of the literatureThe frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populationsHaplotype analysis suggest common founders in carriers of the recurrent BRCA2mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer familiesMultiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer familiesOrigin and distribution of the BRCA2-8765delAG mutation in breast cancerHaplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.Characterization of three new serous epithelial ovarian cancer cell lines.Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian populationForth nightly review: hereditary ovarian carcinoma.Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.Multimodality breast cancer screening in women with a familial or genetic predisposition.Genes implicated in hereditary breast cancer syndromes.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancerContribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.A high proportion of founder BRCA1 mutations in Polish breast cancer families.Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian womenUptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancerGermline TP53 mutational spectrum in French Canadians with breast cancer.Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder populationCommon deletion of SMAD4 in juvenile polyposis is a mutational hotspot.Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary diseasePrevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto RicoGenetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancerFirst case report of an adrenocortical carcinoma caused by a BRCA2 mutationFamilial prostate cancer: the damage done and lessons learnt.Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.
P2860
Q24649433-51CB7AB5-78E5-415E-9A58-83DD987CAA68Q24649532-5DD3BEE4-8C0A-486C-A94E-45343215B096Q24812569-6B039C7C-6EA5-442A-B99D-1D63D6EE840AQ25257213-EAEA3117-A738-42C8-8852-BAAC1E1AD5A3Q27496673-2D9D7AD7-B774-4E0C-BB53-60227149873AQ33289529-163223EC-F0E0-4D81-A38F-AC51A82A621BQ33291268-553121A7-9F4C-424E-AE74-908358A437DEQ33327591-30E1FAD8-36C7-43F4-994D-5A640AEFEAC2Q33338286-75069891-E558-4D94-999C-4B74B92878FAQ33360437-0C17EFF0-B9DB-49CB-A864-057F846E799DQ33419708-AF2A27F8-207A-4993-91DC-C850AB241BF7Q33484437-C0F260DF-27D4-48E2-BC0B-36F218FED731Q33542652-35F4CAAF-A138-4464-8DAF-DE25BBA8F35DQ33684029-95F9ADF8-511F-482D-B351-1FB8E010C673Q33869223-E8C24F06-FEB1-4FE8-8BB5-08B18015DB78Q33894579-051581D9-0316-4004-A1AA-C627A2ABD079Q33915583-9D03B765-AD81-479C-8969-25534231B5EEQ34113283-6BDFDAA6-669D-457E-8562-F4B951330D0DQ34542998-8161D8C7-D758-4B9D-8F32-D29A7B26C461Q34548008-CB7B803B-29BE-405E-A7B4-31CB1212DD90Q34720527-5E9742E1-3FDE-4574-9A28-2BC99440A702Q34783837-44774E15-9D74-41AD-AAD8-C5289EB972F3Q35223166-10485EE3-F901-4150-91FF-6A6E65209DACQ35594607-14643C29-3911-473B-9F73-202B0BE91991Q35618321-1048DC83-67ED-4555-B1D3-C09DD97C6E25Q35619211-E25F3723-BC5E-436E-B1F8-0621F052BA1FQ35758939-B2355297-A41E-4CA5-8101-6174B9C53B73Q35764984-DF982A5F-33A2-4E64-9317-8EC1EAD4797BQ36248459-1CF0B4DD-98F3-45DD-B287-F8581C8C5712Q36494254-941E9F9E-BA2C-4000-99B5-9F2E234289CBQ36620818-FFA20965-0BBC-419F-AA10-FC8B2254DD68Q36643968-38EEB081-275C-4519-90EB-FFECD02C59E0Q36843211-922F7BDE-65D0-415E-8557-2622B9D88B46Q36849117-F64FEEFD-A5A7-4070-ADDF-5B986275E36DQ36849670-B137661B-7E5D-4936-9CB7-C7801F8FCF95Q37004792-9B94BF3E-FB22-4EBF-904F-D08312F75CB9Q37256959-74D78930-145A-464A-82D8-A9AB770163D2Q37553869-348EFC1D-B707-43AE-AF06-CAFD52613414Q37585309-99257257-6FF6-4AD9-8938-0DC0BC36F6A1Q37721626-BE5C8405-B380-4FA7-905B-5A4B94479910
P2860
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@ast
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@en
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@nl
type
label
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@ast
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@en
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@nl
prefLabel
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@ast
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@en
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@nl
P2093
P2860
P50
P356
P1476
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
@en
P2093
P2860
P304
P356
10.1086/302099
P407
P577
1998-11-01T00:00:00Z